GlassScriptPhysician profile
Nora L Cothran
NPI 1467882050
$504,766.50
in general payments reported to CMS, 2019-2025
30 companies · $172K in 2025
The $172K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,684 · 2020: $16K · 2021: $44K · 2022: $99K · 2023: $59K · 2024: $110K · 2025: $172K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $114K · Travel and Lodging: $49K · Consulting Fee: $48K · Food and Beverage: $16K · Entertainment: $130 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,817.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $113,850.00 |
| Travel and Lodging | $48,856.80 |
| Consulting Fee | $47,775.00 |
| Food and Beverage | $15,586.60 |
| Entertainment | $130.17 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $164,087.61 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $158,593.11 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $79,188.70 | 2022-2025 | Rocklatan, Rhopressa, Simbrinza |
| Allergan, INC. | $55,236.13 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $23,268.54 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $9,916.99 | 2019-2021 | |
| Alcon Research LLC | $6,275.00 | 2025 | Rhopressa, Tryptyr |
| Glaukos Corporation | $2,732.40 | 2022-2025 | Radius, Idose, Idosetr |
| Sight Sciences, INC. | $1,636.57 | 2022-2025 | Omni Surgical System, Tearcare System |
| Sun Pharmaceutical Industries INC. | $610.95 | 2019-2024 | |
| Oyster Point Pharma, INC. | $434.21 | 2022-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $425.53 | 2024-2025 | Vevye, Flarex, Iheezo |
| Dompe US, INC. | $378.89 | 2023-2024 | Oxervate |
| New World Medical,INC. | $316.64 | 2023-2024 | Clearpath, Streamline, Kahook Dual Blade |
| Horizon Therapeutics Plc | $241.81 | 2023 | Tepezza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $227.28 | 2019-2022 | |
| Amgen INC. | $208.17 | 2024-2025 | Tepezza |
| Astellas Pharma US INC | $189.39 | 2023 | |
| Ivantis, INC | $138.24 | 2021 | |
| Optos, INC. | $130.17 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Surgical Vision, INC. | $96.79 | 2023 | Lipiflow System Activator (Disposable), Tecnis Simplicity |
| Kala Pharmaceuticals, INC. | $78.69 | 2019-2022 | |
| Lensar, INC. | $78.27 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $67.32 | 2021-2023 | Eylea |
| Tarsus Pharmaceuticals, INC. | $58.71 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $46.92 | 2019 | |
| Thea Pharma INC. | $38.20 | 2022-2024 | Iyuzeh |
| Genentech USA, INC. | $23.75 | 2023 | Vabysmo |
| Akorn, INC. | $22.55 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Cothran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.